AU664768B2 - Nadh and nadph as drugs for treating alzheimer's disease - Google Patents

Nadh and nadph as drugs for treating alzheimer's disease Download PDF

Info

Publication number
AU664768B2
AU664768B2 AU44887/93A AU4488793A AU664768B2 AU 664768 B2 AU664768 B2 AU 664768B2 AU 44887/93 A AU44887/93 A AU 44887/93A AU 4488793 A AU4488793 A AU 4488793A AU 664768 B2 AU664768 B2 AU 664768B2
Authority
AU
Australia
Prior art keywords
nadh
nadph
disease
alzheimer
nicotinamide adenine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44887/93A
Other languages
English (en)
Other versions
AU4488793A (en
Inventor
Jorg Univ.-Prof. DDR. Birkmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU4488793A publication Critical patent/AU4488793A/en
Application granted granted Critical
Publication of AU664768B2 publication Critical patent/AU664768B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU44887/93A 1992-09-30 1993-08-25 Nadh and nadph as drugs for treating alzheimer's disease Ceased AU664768B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4232899A DE4232899C2 (de) 1992-09-30 1992-09-30 Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer
DE4232899 1992-09-30

Publications (2)

Publication Number Publication Date
AU4488793A AU4488793A (en) 1994-04-14
AU664768B2 true AU664768B2 (en) 1995-11-30

Family

ID=6469304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44887/93A Ceased AU664768B2 (en) 1992-09-30 1993-08-25 Nadh and nadph as drugs for treating alzheimer's disease

Country Status (16)

Country Link
US (1) US5444053A (enExample)
EP (1) EP0590321B1 (enExample)
JP (1) JP3384847B2 (enExample)
CN (1) CN1053341C (enExample)
AT (1) ATE162076T1 (enExample)
AU (1) AU664768B2 (enExample)
CA (1) CA2105912C (enExample)
DE (2) DE4232899C2 (enExample)
DK (1) DK0590321T3 (enExample)
ES (1) ES2111104T3 (enExample)
GR (1) GR3026120T3 (enExample)
IL (1) IL106785A (enExample)
MX (1) MX9306049A (enExample)
NO (1) NO303482B1 (enExample)
TW (1) TW231268B (enExample)
ZA (1) ZA936327B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
ES2226817T3 (es) * 2000-04-28 2005-04-01 Mizuno Corporation Estructura de cierre para calzado.
ATE411019T1 (de) * 2001-05-02 2008-10-15 Brni Neurosciences Inst Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
DE10254995B4 (de) * 2002-11-26 2005-02-10 Juelich Enzyme Products Gmbh Verfahren zur enzymatischen Reduktion von NAD und NADP
JPWO2004050099A1 (ja) * 2002-12-03 2006-03-30 協和醗酵工業株式会社 還元型ニコチンアミドアデニンジヌクレオチドまたは還元型ニコチンアミドアデニンジヌクレオチドホスフェイトの安定化方法
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US9186350B2 (en) * 2011-07-12 2015-11-17 Gdb Patent Holdings, Llc Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
CN103340890B (zh) * 2013-06-08 2016-04-27 苏州人本药业有限公司 Nadph作为制备用于防治脑缺血性中风药物方面的应用
WO2019028877A1 (zh) * 2017-08-11 2019-02-14 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用
CN119157897A (zh) * 2023-10-12 2024-12-20 苏州人本药业有限公司 Nadph在制备治疗重性抑郁症、双向抑郁症、脑卒中后抑郁症或神经炎症药物的用途
EP4653001A1 (en) * 2024-05-23 2025-11-26 Universidad Autónoma de Madrid Treatment, diagnosis and/or prognosis of mitochondrial diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345247A2 (de) * 1988-06-03 1989-12-06 Birkmayer, Jörg, Univ.-Prof. DDr. Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814339A (en) * 1986-02-11 1989-03-21 Advanced Biologics, Inc. Treatment for Alzheimer's disease
CA1336169C (en) * 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345247A2 (de) * 1988-06-03 1989-12-06 Birkmayer, Jörg, Univ.-Prof. DDr. Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
CN1089474A (zh) 1994-07-20
AU4488793A (en) 1994-04-14
CA2105912A1 (en) 1994-03-31
TW231268B (enExample) 1994-10-01
CN1053341C (zh) 2000-06-14
US5444053A (en) 1995-08-22
DE4232899C2 (de) 1995-02-23
IL106785A0 (en) 1993-12-08
NO303482B1 (no) 1998-07-20
NO933321D0 (no) 1993-09-17
IL106785A (en) 1997-09-30
EP0590321B1 (de) 1998-01-14
ES2111104T3 (es) 1998-03-01
DE4232899A1 (de) 1994-03-31
ATE162076T1 (de) 1998-01-15
GR3026120T3 (en) 1998-05-29
NO933321L (no) 1994-04-05
EP0590321A1 (de) 1994-04-06
DE59307982D1 (de) 1998-02-19
JP3384847B2 (ja) 2003-03-10
MX9306049A (es) 1994-05-31
ZA936327B (en) 1994-03-22
JPH06192106A (ja) 1994-07-12
CA2105912C (en) 2000-11-14
DK0590321T3 (da) 1998-09-14

Similar Documents

Publication Publication Date Title
CA2105912C (en) Nadh and nadph as drugs for treating alzheimer's disease
US4816456A (en) Administration of monoamine acridines in cholinergic neuronal deficit states
US5965571A (en) Cholinesterase inhibitors for treatment of Parkinson's disease
AU592121B2 (en) Method for alleviation of panic disorders
JPH045648B2 (enExample)
US5837701A (en) Composition and method for treating conditions associated with symptoms of unspecified retarded maturation
US4481206A (en) Spiro succinimide derivative in the treatment of dementia of the Alzheimer type
CA2216479A1 (en) Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
JP2732109B2 (ja) 痴呆治療剤
JPH0232015A (ja) 薬剤の製造のためのモノ置換セレン有機化合物の使用、ならびにそれから製造される薬剤およびその薬剤の製造方法
JPH04501724A (ja) 骨粗しょう症の治療
US4278667A (en) Method of treating tardive dyskinesia by oral dosage form of a physostigmine compound
Silverstone A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder
US5876751A (en) Antispasmodic and antinflammatory composition and a process for the manufacture thereof
US20040058947A1 (en) Composition for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
KR20120081151A (ko) 통증 조절 및 탈수초 손상의 역전에서의 ｎ?2?하이드록시?에틸?피페라진?ｎ‘?2?에탄 설폰산（ｈｅｐｅｓ）의 역할
DE69516602T2 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie
JPH07507280A (ja) （−）−メトリフォネート含有薬剤
KR20050092106A (ko) 현기증치료용 화합물 조제
JPH05504765A (ja) 神経学的疾患を治療するための４，４′―〔９ｈ―フルオレン―９―イリデンビス（メチレン）〕ビスピリミジン
AU3484493A (en) Brofaromine as an agent for treating post-traumatic stress
KR20230163367A (ko) 실행 기능 장애를 치료하기 위한 조합 요법
Webb et al. Guilt and sexually transmitted diseases
AU2001282510A1 (en) Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
Kim et al. A Case of Cryptococcosis treated with 5-fluorocytosine